0000000000322573
AUTHOR
Elvira Mora Casterá
Trasplante alogénico de progenitores hematopoyéticos en adultos con leucemia linfoblástica aguda
Los avances terapéuticos en la leucemia linfoblástica aguda (LLA) han sido notables en los últimos años con la incorporación de esquemas de quimioterapia más intensivos, los inhibidores de tirosina quinasa y los grandes avances en el campo del trasplante alogénico de progenitores hematopoyéticos (TPH). El objetivo del estudio ha sido analizar los resultados del TPH en una amplia serie de pacientes adultos con LLA y proponer ideas de mejora. Para ello, un primer estudio ha evaluado exhaustivamente el tipo de donante, fuentes de progenitores hematopoyéticos e intensidad del acondicionamiento en una serie retrospectiva de 211 pacientes con LLA del Hospital Universitario y Politécnico La Fe (HU…
Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only curative treatment for myelofibrosis (MF), but its associated toxicity remains high. Prognostic risk models are widely used in clinical practice to select those MF patients who are more likely to benefit from transplantation. Recently, a new prognostic model, the Myelofibrosis Transplant Scoring System (MTSS), has been developed to predict the outcome of MF patients undergoing allo-HCT (Gagelmann N et al, Blood 2019). We aimed to evaluate the performance of such model in an independent series of patients. Methods: This is a retrospective study that included all adult patients who underwent first allo…
Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations
Introduction : The 20q deletion [del(20q)] is a recurrent chromosomal aberration in myelodysplastic syndromes (MDS) and, as a single abnormality, is associated according to the Revised International Prognostic Scoring System (IPSS-R) with a favorable outcome. However, the breakpoint of del(20q) is very heterogeneous and may cause deletion of the ASXL1 gene (20q11.21). This gene is an important epigenetic regulator of hematopoiesis and its mutations have been associated in MDS with a shorter overall survival (OS) and a lower response to azacitidine (AZA). Aim: To assess the incidence, prognostic value and impact on response to AZA of ASXL1 chromosomal alterations and genetic mutations in MDS…